Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. Reply.
사설/논평
0/5 보강
APA
Yang JC, Sethi S, Cho BC (2026). Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. Reply.. The New England journal of medicine, 394(9), 935-936. https://doi.org/10.1056/NEJMc2517120
MLA
Yang JC, et al.. "Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. Reply.." The New England journal of medicine, vol. 394, no. 9, 2026, pp. 935-936.
PMID
41740051 ↗
같은 제1저자의 인용 많은 논문 (5)
- Linking Lymphedema, Chronic Inflammation, Oxidative Stress, Alzheimer Disease, and Potential Role of Lymphaticovenous Anastomosis.
- Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
- Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301.
- Managing crawling-type gastric adenocarcinoma with endoscopic techniques and postoperative monitoring.
- Impact of retrograde anastomosis during supermicrosurgical lymphaticovenous anastomosis for cancer-related lower limb lymphedema: A retrospective cohort propensity-score-matched outcome analysis.